Literature DB >> 33945832

Mitral Surgery After Transcatheter Edge-to-Edge Repair: Society of Thoracic Surgeons Database Analysis.

Joanna Chikwe1, Patrick O'Gara2, Stephen Fremes3, Thoralf M Sundt4, Robert H Habib5, James Gammie6, Mario Gaudino7, Vinay Badhwar8, Marc Gillinov9, Michael Acker10, Georgina Rowe11, George Gill11, Andrew B Goldstone10, Thomas Schwann12, Annetine Gelijns13, Alfredo Trento11, Michael Mack14, David H Adams15.   

Abstract

BACKGROUND: Transcatheter edge-to-edge (TEER) mitral repair may be complicated by residual or recurrent mitral regurgitation. An increasing need for surgical reintervention has been reported, but operative outcomes are ill defined.
OBJECTIVES: This study evaluated national outcomes of mitral surgery after TEER.
METHODS: The Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database was used to identify 524 adults who underwent mitral surgery after TEER between July 2014 and June 2020. Emergencies (5.0%; n = 26), previous mitral surgery (5.3%; n = 28), or open implantation of transcatheter prostheses (1.5%; n = 8) were excluded. The primary outcome was 30-day or in-hospital mortality.
RESULTS: In the study cohort of 463 patients, the median age was 76 years (interquartile range [IQR]: 67 to 81 years), median left ventricular ejection fraction was 57% (IQR: 48% to 62%), and 177 (38.2%) patients had degenerative disease. Major concomitant cardiac surgery was performed in 137 (29.4%) patients: in patients undergoing isolated mitral surgery, the median STS-predicted mortality was 6.5% (IQR: 3.9% to 10.5%), the observed mortality was 10.2% (n = 23 of 225), and the ratio of observed to expected mortality was 1.2 (95% confidence interval [CI]: 0.8 to 1.9). Predictors of mortality included urgent surgery (odds ratio [OR]: 2.4; 95% CI: 1.3 to 4.6), nondegenerative/unknown etiology (OR: 2.2; 95% CI: 1.1 to 4.5), creatinine of >2.0 mg/dl (OR: 3.8; 95% CI: 1.9 to 7.9) and age of >80 years (OR: 2.1; 95% CI: 1.1 to 4.4). In a volume outcomes analysis in an expanded cohort of 591 patients at 227 hospitals, operative mortality was 2.6% (n = 2 of 76) in 4 centers that performed >10 cases versus 12.4% (n = 64 of 515) in centers performing fewer (p = 0.01). The surgical repair rate after failed TEER was 4.8% (n = 22) and was 6.8% (n = 12) in degenerative disease.
CONCLUSIONS: This study indicates that mitral repair is infrequently achieved after failed TEER, which may have implications for treatment choice in lower-risk and younger patients with degenerative disease. These findings should inform patient consent for TEER, clinical trial design, and clinical performance measures.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  mitral regurgitation; mitral repair; mitral valve replacement; transcatheter edge-to-edge mitral repair

Mesh:

Year:  2021        PMID: 33945832     DOI: 10.1016/j.jacc.2021.04.062

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  4 in total

1.  Imperatives in mitral valve interventions: long-term survival, valve durability and valve performance.

Authors:  Michael Ibrahim; W Clark Hargrove
Journal:  Nat Rev Cardiol       Date:  2021-08       Impact factor: 32.419

2.  Case Report: Living on the Edge-Transcatheter Mitral Valve Repair Related Infective Endocarditis.

Authors:  Nicole Lewandowski; Ehssan Berenjkoub; Eduard Gorr; Marc Horlitz; Peter Boekstegers; Mirko Doss; Sami Sirat; Dennis Rottländer
Journal:  Front Cardiovasc Med       Date:  2022-01-06

3.  Transcatheter Edge-to-Edge Mitral Valve Repair in Functional Mitral Regurgitation. Does it Pass Muster? Still Leaving Plenty to Be Desired.

Authors:  Ovidio A García-Villarreal
Journal:  Braz J Cardiovasc Surg       Date:  2022-05-02

4.  Mitral valve surgery after failed transcatheter edge-to-edge repair.

Authors:  Piotr Mazur; Arman Arghami; Clark Zheng; Mohamad Alkhouli; Hartzell V Schaff; Joseph Dearani; Richard C Daly; Kevin Greason; Juan A Crestanello
Journal:  JTCVS Tech       Date:  2022-05-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.